Back to search results

Investigations of Dementia in Parkinson Disease

This study aims to understand different types of dementia in people with Parkinson's disease (PD). Researchers will use special brain scans called Pittsburgh B (PIB) Positron Emission Tomography (PET) and Vesicular Cholinergic Transport (VAT) PET. These scans help identify abnormal proteins in the brain. The goal is to find out which people with PD are at risk for dementia and what causes it. You may be able to join if you are 50 or older and have certain symptoms of Parkinson's disease, such as tremor or stiffness. The study is hoping to include 320 participants and will measure its main goal in 2030.

Study design
This is an observational study, meaning researchers will observe participants without providing a specific treatment. It plans to include a total of 320 participants.
What's involved
You would undergo brain imaging procedures using PIB and VAT during PET scans. The study is described as long-term.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint for this study will be measured in 2030.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02763683

Investigations of Dementia in Parkinson Disease

Recruiting
Not specifiedAges 50+Observational
Washington University School of Medicine
~320 participants
Updated 2026-05-08 on ClinicalTrials.gov
What's tested:PiB and VAT

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Investigations of Dementia in Parkinsons Disease
Measured over 2030

Conditions

Parkinsons

Explore related trials

DementiaParkinson Disease

Where it's being run

1 sites across 1 states
Missouri1

Study leadership

  • Joel S Perlmutter, MD · PRINCIPAL_INVESTIGATOR · Washington University School of Medicine
  • MD · PRINCIPAL_INVESTIGATOR

Who to contact

Andrea Slavik, RN, BSN
[email protected]
314 273 8313
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

PD patients must exhibit three of the following cardinal signs: rest tremor, rigidity, bradykinesia, or postural instability; or two of these features with one of the first three displaying asymmetry.

Exclusion

history of head trauma, major neurological or psychiatric diseases other than Parkinson disease and dementia, e.g. stroke, multiple sclerosis, depression or schizophrenia.
severe systemic diseases.
inability to lie still for 90 minutes.
metallic implants, pacemakers, or any other contraindication to MRI.
refusal to consent to brain donation.

What this trial measures

  • Investigations of Dementia in Parkinsons Disease2030

    The investigators will perform memory/thinking testing, Lumbar puncture (LP), Magnetic Resonance Imaging (MRI) and (PET) scans to help to determine the cause(s) of memory and thinking in Parkinson Disease. The memory and thinking testing by phone on average at 1.5 years through study completion and then in person on average at 3 years through study completion, this will help monitor if there is any decline in memory and thinking. The Lumbar Puncture is done on willing participants on average at 3 years through study completion to assess for any abnormal proteins and correlate these with any changes in memory and thinking. The MRI is done on average at 3 years through study completion for any abnormal signs or changes in regards to dementia at 3 years. The (PiB) \& (VAT) PET scans will be performed on average at 3 years through study completion, which will be analyzed to assess for changes in regards to abnormal proteins and signs of dementia.